Le Lézard
Classified in: Health, Science and technology

Global Cell Therapy Market Report 2023: Advancements in Biotechnology Drives Growth - ResearchAndMarkets.com


The "Global Cell Therapy Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.

The global cell therapy market size attained a value of USD 13.8 billion in 2022. The market is likely to grow at a CAGR of 18.10% during the forecast period of 2023-2031 to attain a value of USD 61.2 billion by 2031.

Cell therapy has emerged as a rapidly growing and innovative segment of the global healthcare industry. It encompasses a diverse range of therapeutic approaches, including regenerative medicine, immunotherapy, and gene therapy, aimed at treating various diseases and disorders by harnessing the power of living cells.

The global cell therapy market is anticipated to witness significant growth in the coming years, driven by advancements in biotechnology, increasing investment in research and development, and a rising prevalence of chronic diseases and genetic disorders.

Factors like rising incidence of cancer, cardiovascular diseases, and autoimmune disorders drive the demand for innovative and effective treatment options, are fuelling the growth of the cell therapy market. Developments in gene editing technologies, such as CRISPR/Cas9, have opened new possibilities for cell therapies, offering improved efficacy and safety profiles.

Governmental and private investments in cell therapy research have led to a robust pipeline of experimental treatments, which are expected to enter the market in the coming years.

Market Segmentation

The market can be categorized into cell type, therapy type, therapeutic area, end user, and region.

by Cell Type

by Therapy Type

by Therapeutic Area

by End User

by Region

North America

Europe

Asia Pacific

Latin America

Middle East and Africa

Key Players in the Global Cell Therapy Market

The report gives an in-depth analysis of the key players involved in the cell therapy market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

For more information about this report visit https://www.researchandmarkets.com/r/d8g48x

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


These press releases may also interest you

at 20:50
Overture Launches Inner Circles: Redefining Private Attorney Referral Networks
Overture.law, the nation's leading attorney-to-attorney referral platform, launches their transformative new product, Inner Circles. This groundbreaking product empowers attorneys, law schools, bar associations, and affinity groups to build private...

at 20:09
Not Just 1, But 2: BASIS Charter Schools Celebrates a Pair of Students Named Presidential Scholars by the U.S. Department of Education
BASIS Charter Schools proudly announce that two of its exceptional students have been named 2024 U.S. Presidential Scholars by the U.S. Department of Education. Matteo N. Huish from BASIS Mesa and Sruti Peddi from BASIS Scottsdale have been...

at 20:00
Greenberg Traurigs Kemal Hawa to Moderate Panel at DICE East 2024
Kemal Hawa, co-chair of the Digital Infrastructure, Data Center and Cloud Computing Practice of global law firm Greenberg Traurig, LLP, will moderate a panel at DICE East 2024 May 22 in Reston, Virginia. Hawa, a member of the firm's Washington,...

at 19:45
WIO Taps Gracenote to Revolutionize Television Broadcast Reporting
WIO LLC, parent company of the global TV broadcast airings platform, WIOprotm, has announced a new strategic agreement with Gracenote, the global content data business unit of Nielsen, to address the longstanding challenge of accurately tracking and...

at 19:35
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...

at 19:00
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...

More news about Science and technology...


News published on and distributed by: